Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: The Reform trial

Diabetes Care

Volumn 43, Issue 6, 2020, Pages 1356-1359

  Singh, Jagdeep S S ^a   Mordi, Ify R ^a   Vickneson, Keeran ^a   Fathi, Amir ^a   Donnan, Peter T ^a   Mohan, Mohapradeep ^a   Choy, Anna Maria J ^a   Gandy, Stephen ^b   George, Jacob ^a   Khan, Faisel ^a   Pearson, Ewan R ^a   Graeme Houston, J ^a   Struthers, Allan D ^a   Lang, Chim C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NHS TAYSIDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN; KETONE; LOOP DIURETIC AGENT; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ACUTE CORONARY SYNDROME; AGED; BLOOD PRESSURE REGULATION; BODY WEIGHT LOSS; CANCER MORTALITY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONFERENCE PAPER; CONTROLLED STUDY; DIURETIC THERAPY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE REMODELING; HEMATOCRIT; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; COMPLICATION; DIABETIC ANGIOPATHY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; BENZHYDRYL COMPOUNDS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLUCOSIDES; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; PLACEBOS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85085264878     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc19-2187     Document Type: Conference Paper

References (12)

1. Packer M. Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes. Diabetes Care 2018;41:11–13
2. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31–39
3. McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008
4. Singh JS, Fathi A, Vickneson K, et al. Research into the effect of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol 2016;15:97
5. Mordi I, Jhund PS, Gardner RS, et al. LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs. JACC Cardiovasc Imaging 2014;7:561–569
6. Mordi I, Bezerra H, Carrick D, Tzemos N. The combined incremental prognostic value of LVEF, late gadolinium enhancement, and global circumferential strain assessed by CMR. JACC Cardiovasc Imaging 2015;8:540–549
7. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 2011;4:98–108
8. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effectson mortality in patients with heart failure and reducedejection fraction: ameta-analytic approach. J Am Coll Cardiol 2010; 56: 392–406
9. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 2016;39:1115–1122
10. Ferrannini E, Baldi S, Frascerra S, et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 2017;40: 771–776
11. Mazer CD, Hare GMT, Connelly PW, et al. Effect of empagliflozin on erythropoietin levels, iron stores,andredbloodcellmorphologyinpatients with type 2 diabetes mellitus and coronary artery disease. Circulation 2020;141:704–707
12. Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. J Am Heart Assoc 2019;8:e013389